ADVIKLA

MPS Pharma Share Price

₹4.13 -0.01 (-0.24%)

21 Nov, 2024 15:58

SIP TrendupStart SIP in ADVIKLA

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 4.56%
  • Over 3 Month + 7.55%
  • Over 6 Month + 24.02%
  • Over 1 Year + 48.03%
SIP Lightning

Smart Investing Starts Here Start SIP with MPS Pharma for Steady Growth!

Invest Now

MPS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

MPS Pharma Financials

MPS Pharma Technicals

EMA & SMA

Current Price
₹4.13
-0.01 (-0.24%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹3.81
  • 50 Day
  • ₹3.39
  • 100 Day
  • ₹2.85
  • 200 Day
  • ₹2.34

Resistance and Support

4.13 Pivot Speed
  • R3 4.15
  • R2 4.14
  • R1 4.14
  • S1 4.13
  • S2 4.12
  • S3 4.12

What's your outlook on MPS Pharma?

You can only vote for once

MPS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-13 Quarterly Results
2024-05-30 Audited Results
2024-03-26 Independent Director Meeting
2024-02-13 Quarterly Results

MPS Pharma F&O

MPS Pharma Shareholding Pattern

No data available.

About MPS Pharma

  • NSE Symbol
  • ADVIKLA
  • BSE Symbol
  • 531686
  • ISIN
  • INE537C01019

Similar Stocks to MPS Pharma

MPS Pharma FAQs

MPS Pharma share price is ₹4 As on 21 November, 2024 | 15:44

The Market Cap of MPS Pharma is ₹7.9 Cr As on 21 November, 2024 | 15:44

The P/E ratio of MPS Pharma is -8.7 As on 21 November, 2024 | 15:44

The PB ratio of MPS Pharma is 4 As on 21 November, 2024 | 15:44

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23